Tim Opler

🎙️Excited to share my recent conversation on "The Business of HLTH" podcast where we delve into the dynamic intersection of finance and #lifesciences. As a #CFO dedicated to advancing the industry, I discuss the nuances of venture investing, M&A, and strategic financial planning that can propel life sciences organizations forward. 🔗Tune in to gain insights into how we at Tialma provide tailored CFO solutions that not only manage but enhance the financial and operational aspects of life sciences companies, ultimately maximizing shareholder value. Whether you're involved in biotech, medtech, or looking to understand the financial intricacies of the industry, this episode offers valuable perspectives. 👉Listen to the episode here: https://lnkd.in/e6Yx8swQ Feel free to connect and discuss how strategic financial leadership can make a measurable impact in the life sciences sector.

12

4 Comments

Imagine swallowing the competition whole. That's what many players in tech do via roll-up strategies, gobbling up smaller firms to deliver richer solutions and amass greater market share. Where else are roll-up strategies common? // HEALTHCARE Picture being a patient at a medical practice that’s been part of a roll-up in Healthcare Services. It's an industry ripe for roll-ups due to its fragmented nature and potential for greater efficiency. // CONSUMER SERVICES Or let's say you needed your HVAC serviced, and notice your local repairman is now part of a bigger Consumer Services entity? Centralized management and scale economy turn these localized businesses into roll-up targets. // FINANCIAL SERVICES Think about your insurance agent or wealth management advisor. They're working in complex, highly regulated environments. In the Financial Services sector, roll-ups offer an effective way to consolidate expertise, streamline operations, and enhance customer offerings. // MANUFACTURING Now, imagine driving past factories under a new name — the result of Manufacturing and Industrial Services roll-ups. Bulk purchasing reduces costs, enhances production capabilities, and expands geographical footprints. // REAL ESTATE Lastly, envision your real estate brokerage firm. The industry sees roll-ups as a strategic move to increase market penetration, enhance service offerings, and hike up portfolio value. Roll-ups play a huge role in most industries, rather like a snowball rolling downhill, gaining momentum, and size. Are you seeing roll-ups in your sector or considering M&A?

11

1 Comment

The biotech sector is evolving rapidly, making resilience more critical than ever. I’m pleased to share our team's report, which highlights this dynamic shift. It’s inspiring to see how the biotech industry leverages its intrinsic innovative mindset to explore new avenues for fundraising, IPOs, and collaborations. Cindy (Xin) XiongLuna Ji Paul Lu Donnie McGrathBruce BoothRicky SunSrini AkkarajuJeffrey TongAnna FanNandita ShangariLianshan ZhangMichael Yu Our latest report, "Thriving Amid Capital Winter: How Biotech Companies Leverage Creative Strategies for Growth & Successful Exits," highlights innovative strategies from leading companies, including Gracell Biotechnologies & AstraZeneca, Novartis & SanReno Therapeutics, @Gyre Therapeutics & @Catalyst Biosciences, Bayside Lakeshore Bio & Apollomics, Shanghai Allist Pharmaceuticals Co., Ltd & ArriVent Biopharma, Hengrui Pharma Co.,Ltd & Hercules, @KeyMed Bio & Belenos, Genor & TRC 20024, EpimAb Biotherapeutics, Inc. & Vignette Bio, Bayer, RTW Investments, LP & CORXEL Pharmaceuticals, Sanofi & Innovent Biologics, and CBC Group & Paratek Pharmaceuticals, Forsite Capital, RTW Investments, LP From M&A strategies and the NewCo model to royalty-based financing and strategic collaborations, learn how these companies are navigating market challenges, driving innovation, and securing growth opportunities. 💡 Discover actionable insights to position your biotech business for success in today’s capital-constrained environment. Access full Report: 🔗 https://lnkd.in/dEdb3Pwd Let’s navigate this capital winter together and build a stronger, more sustainable biotech future. hashtag #biotech hashtag #capitalmarkets hashtag #growthstrategies hashtag #innovation hashtag #MSQVentures hashtag #NewReport hashtag #biotechindustry

11

Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development

118

5 Comments

Karius’s journey started ten years ago at Stanford, SoftBank has been along for the last four, and today we’re proud to open its next chapter alongside both long-standing and new supporters. The Karius test brings the power of NGS to infectious disease, where it solves not one diagnostic problem but >1,000 at once, mining microbial DNA with ML to identify pathogens and drug-resistance markers. This helps reduce the guesswork of treating infections in the most vulnerable patients, including one half of cancer deaths caused by infection rather than the cancer. This technology has already transformed the care of 10,000s of patients, but we’re just getting started. It’s been a privilege to observe Karius’s remarkable innovation engine that’s set to impact many more diverse clinical settings, and we are confident this financing is the rocket fuel to get there. Here’s to Karius’s next ten years. Vali Barsan, Sumer Juneja

35

1 Comment

Healthcare Innovation and Investment News for the week from HDIG HDIG Search, Consulting and Venture HDIG is an ecosystem with a searchable database of hospital healthcare venture, innovation centers, tech transfer offices and their portfolio companies. It would assist you in understanding the landscape of partnerships, performance, and contacts. Early-stage companies use it to find partners and funding for their pilots, or even professional firms or tech companies depending on their needs. Launched this year with nearly 10,000 companies, hospitals, and funds, get full access for a special monthly subscription of only $100 and you can cancel at anytime, this would include building your profile. Learn more about our Acceleration Pilot Program, paid pilots, reverse studio model and other research and services. #HDIG #HealthcareInnovation #HealthcareVenture #HospitalInnovation

3

TL;DR: Solving a fundamental point of friction in US health care: affordability The LEAD team is excited to back The WiTT Group and Rahul Mahadevan in their latest financing round led by Sopris Capital to expand their impact efforts of distributing non-clinical support to patients more efficiently! "Financial toxicity for patients undergoing treatment in the U.S. healthcare system is a critical issue that needs urgent attention. What excites us about backing WiTT is its platform's unique ability to align incentives across key stakeholders and support patients in need in the community. It efficiently delivers financial and non-financial assistance to patients, driving improved treatment compliance for healthcare providers. We're excited to support their commercial expansion as they grow the most valuable, proprietary patient dataset focused on self-reported social determinants of health." CC: Thomas H. Rudy Kaiwen Liu Matthew Foran Sopris Capital Taylor Paul Abinav Sankar Charlie Regis Kendel Fiorentino

17

1 Comment

As I said right at the start of this week's The Heart of Healthcare Podcast, Shivdev Rao is one of the most exceptional founders I have ever worked with. He is also a great human being. In this week's episode he shares what is it like leading the 🚀 that is Abridge and some awesome life lessons. IMHO this is a great listen for founders building in both the AI and healthcare fields!

56

3 Comments

[New Compounders Podcast] We are back with a fascinating episode with a public company CEO from the healthcare/medical devices space. After working at Baxter and Stryker, Jim Cunniff became CEO of ELMD in 2023 and has brought a new level of focus and urgency to the Electromed. In this conversation, covered: ·      Why Jim decided to take the CEO role at Electromed; ·      What is special about the company's main product, the SmartVest, as well as the drivers of growth; ·      Why Bronchiectasis remains an underdiagnosed condition; ·      What he has learned from being an operating partner at Shore Capital; and ·      How the company generates 70%+ gross margins. I hope you enjoy the episode: https://lnkd.in/gvtqrhwi

8

A series for those interested in listening to transformational healthcare

3

Disclaimer: This memo is for research purposes and reflects my interest in writing an investment blog. It should not be considered a recommendation for investment. I have no financial interest or gain from the company discussed, which was selected randomly for my series of memos. During my recent travels, I have been diving deep into the antibody-drug conjugate (ADC) space, which has been particularly hot with multiple high-profile acquisitions. While researching Cancer Research Horizon's portfolio, I came across Myricx Bio. Myricx stands out with its novel N-Myristoyltransferase (NMT) inhibitor payload platform, offering a fresh approach in the crowded ADC space. With recent acquisitions like Pfizer-Seagen ($43B), Genmab-ProfoundBio ($1.8B), and J&J-Ambrx ($2B), the timing couldn't be better for innovative ADC technologies. Their pipeline targets both established markers (HER2, Trop2) and emerging ones (B7-H3), with their lead candidate MYX2449 heading toward IND-enabling studies. What's particularly intriguing is their preclinical data showing superior efficacy to existing ADCs in several models. Speaking of exciting UK biotech spin-outs, I'm particularly excited about Amphista Therapeutics in the targeted protein degradation (TPD) space and Constructive Bio in synthetic biology. What’s next? This might be my second-to-last biotech deep dive for the year. I'm planning one more piece on targeted protein degradation before expanding my horizons into fintech and climate tech. Stay tuned for my upcoming analysis building on my previous GPay evolution piece, focusing on tokenization in India's fintech landscape. #Biotech #ADC #Investmentmemo #investmentthesis #lifesciences #oncology #VCs #acquisitiontargets

4

One of the most exciting questions from this interview was "what key attributes do private equity firms seek in targeting healthcare, biotech, and life science companies for acquisition?". Private equity firms are increasingly attracted to the healthcare, biotech and life sciences industries due to their resilience against economic cycles. Attributes that PE firms prioritize include: Stability and Growth Potential: Companies that demonstrate consistent revenue growth and have a solid track record of performance are highly attractive. The ability to withstand economic downturns and maintain steady growth is a crucial factor. Service and Software Focus: Companies that provide essential services and software solutions within the healthcare ecosystem are less vulnerable to regulatory changes and scrutiny, making them reliable investment targets. Regulatory Compliance and Low Risk: PE firms typically avoid companies with high science risk. Instead, they favor businesses with well-established products, services and technology. Specialization and Expertise: Many PE firms seek companies with specialized knowledge and capabilities that align with their strategic focus areas, ensuring they can add value and drive growth post-acquisition. Thank you to the Los Angeles Times for inviting me to participate in this issue! I am honored to be able to contribute to this piece. If you'd like to discuss any of the insights from this issue, reach out to me directly. #privateequity #lifesciences #healthcareservices #biotech #investmentbanking #businessvaluation

20

TL;DR - 1) Mario & team at Oscar are testing (and writing about) LLMs in real-world healthcare applications and their blog is a good read for the AI-curious. 2) o1, even in preview format, is a must-try to address complex problems where 4o might not have delivered consistent results. Hopefully folks are starting to set up AI-sandboxes with test data and tinkering!

49

1 Comment

🚨 Healthcare M&A Update – September 2024 🚨 The healthcare sector remains active with significant merger and acquisition activity in Q2 2024. The median deal value stood at $50M, with strategic buyers driving 93% of transactions. Below are some notable M&A deals announced publicly this year: 💊 ANI Pharmaceuticals acquired Alimera Sciences for $400M in June. 💉 GSK completed its acquisition of Elsie Biotechnologies for $50M in the same month. 🏥 Nordson Medical Corporation secured Atrion Corporation for $815M in May. 🧬 Novartis AG expanded its oncology portfolio by acquiring Mariana Oncology for $1.8B in May. 🌍 Johnson & Johnson made headlines with its $13.9B acquisition of Shockwave Medical in April. The healthcare M&A space shows no signs of slowing down. Stay tuned for more updates as we move through the rest of 2024! #HealthcareMergers #MergersAndAcquisitions #HealthcareM&A #StrategicDeals #BusinessGrowth #PharmaAcquisitions #HealthcareInnovation #IndustryUpdates #CorporateStrategy #FinancialTrends #MedTech #BiotechAcquisitions

2

1 Comment

Let me know if you would like more information on this!

4

Jonathan Norris and team have published their latest report tracking trends for the healthcare venture industry for 1H 2024. Check it out below

37

2 Comments

Ever stumble into something and think “holy ****, how does everyone not realize this is here?” That’s what gateway.racap.com is for biotech executives/directors and everyone who wants to be one. It’s still an emerging gem where my colleagues and I have been storing pearls in the form of interviews and articles and slide decks that explain countless things about biotech. You can even assess the strength of your board across 20+ dimensions & discover people who could fill gaps. Learn how to run efficient board meetings (shave 4 hours down to 1-2; hint: elephant slide, core value prop, and agenda), how low fees could be on financing instruments, real differences between crossover and other rounds, how to teach value of equity to employees, how to extract from your existing investors what they really want to invest in an IPO and at what price, how to handle M&A negotiations, the utility of low-ego polymaths, how to avoid overstaffing, and so much more. When we learn new things, Gateway is where we share what we learn. And if you have something you want to teach, just let me know. Gateway features the wisdom of many people from across our ecosystem. I wrote “The Entrepreneur’s Guide to a Biotech Startup” 20 years ago. Gateway is the ever evolving sequel. Hope you discover it (if you haven’t already) and pass it onto to others. Because we all make fewer mistakes when we learn from others. And with society demanding that we do more with less, there’s really no excuse for repeating mistakes, right? Peter #biotech RA Capital Management

278

4 Comments

The healthcare landscape is rapidly evolving, driven by advancements in technology and a deeper understanding of patient care. I had the pleasure of speaking with Ambar Bhattacharyya, Co-Managing Partner at Maverick Ventures, on the latest episode of The Full Ratchet. Ambar has partnered with numerous billion-dollar companies like hims & hers, Cityblock Health, Devoted Health, and ConcertAI. His unique journey from rural America to becoming a prominent figure in venture capital offers invaluable insights into the future of healthcare and technology. We discuss his investment strategy at Maverick Ventures, the megatrends shaping healthcare, the impact of AI on the industry, and the importance of integrated care. Ambar also shares his thoughts on the challenges and opportunities in healthcare investment, offering a comprehensive view of what lies ahead. Check out TFR Episode 438 to catch our conversation. You'll be glad you listened. Link to the full episode is in the comment section below.

117

8 Comments